Skip to content

Screening of Niemann-Pick Disease, Type C in a Psychiatric Population

Study Qbout the Screening of Niemann-Pick Disease, Type C in a Psychiatric Population

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02841358
Acronym
NPCPsy
Enrollment
22
Registered
2016-07-22
Start date
2013-12-31
Completion date
2016-12-31
Last updated
2017-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric Adults Patients

Keywords

Niemann-Pick Disease, Type C, Psychiatric, Psychotic disorders

Brief summary

Niemann-Pick disease, Type C is a rare genetic disorder characterized by a failing in intracellular cholesterol transport, inducing an accumulation of sphingolipids in the brain. Neurological signs are at the forefront of the disease. There are also psychiatric signs of psychotic kind among 28 to 45 % of patients according to studies, and a thirty cases were published. These signs can be concomitant with neurological signs or precede them. Is is likely that psychotic disorders are the first signs of a Niemann-Pick disease not yet non encore diagnosed for some patients. Yet, no prevalence study for this disease in a psychiatric population of patients currently exists. In response to this problem this study proposes to search patients whose disease could be of organic origin or patients whose disease is suspected, based on clinical data. The diagnosis will be confirmed certified with a genetic and/or biochemical test.

Detailed description

The aim of this study is to search among a population psychotic adult patients, the ones that present a Type C Niemann-Pick disease in order to to estimate the prevalence.

Interventions

BIOLOGICALBlood sampling
BIOLOGICALBiopsy

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hallucinations visual * Confusion * Catatonia * Significant fluctuation of symptoms * Unusual or paradoxical reaction to the treatment * Progressive cognitive deterioration

Exclusion criteria

* Patients under 18 years * Patients unable to give their free consent and without a legal representative * Breastfeeding or pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Blood sampling3 minutesFor patients with suspicion of Type C Niemann-Pick Disease, to determine blood/plasma oxysterols level.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026